Available online 5 August 2022

The screening of the pharmacological components of Glycyrrhizae Radix et Rhizoma (Gan Cao, GC) in the treatment of pneumonia was reported for the first time.

GC was beneficial for the treatment of lung inflammation or damage by down-regulating the activity of iNOS.

The molecular binding between glycyrrhetinic acid and iNOS was verified, and glycyrrhetinic acid was highly effective in down-regulating iNOS activity.

Glycyrrhizae Radix et Rhizoma, a traditional Chinese medicine also known as Gan Cao (GC), is frequently included in clinical prescriptions for the treatment of pneumonia. However, the pharmacological components of GC for pneumonia treatment are rarely explored. Gan An He Ji oral liquid (GAHJ) has a simple composition and contains GC liquid extracts and paregoric, and it has been used clinically for many years. Therefore, GAHJ was selected as a compound preparation for the study of GC in the treatment of pneumonia. We conducted an in vivo study of patients with pneumonia undergoing GAHJ treatments for three days. Using the intelligent mass spectrometry data-processing technologies to analyze the metabolism of GC in vivo, we obtained 168 related components of GC in humans, including 24 prototype components and 144 metabolites, with 135 compounds screened in plasma and 82 in urine. After the analysis of the metabolic transformation relationship and relative exposure, six components (liquiritin, liquiritigenin, glycyrrhizin, glycyrrhetinic acid, daidzin, and formononetin) were selected as potential effective components. The experimental results based on two animal pneumonia models and the inflammatory cell model showed that the mixture of these six components was effective in the treatment of pneumonia and lung injury and can effectively downregulate the level of inducible nitric oxide synthase (iNOS). Interestingly, the glycyrrhetinic acid exhibited the strongest inhibition on iNOS and the highest exposure in vivo. The following molecular dynamic simulations indicated a strong bond between glycyrrhetinic acid and iNOS. Thus, the current study provides a pharmaceutical basis for GC and reveals the possible corresponding mechanisms in pneumonia treatment.

Glycyrrhizae Radix et Rhizoma

pneumonia

active components

inducible nitric oxide synthase

glycyrrhetinic acid

© 2022 Published by Elsevier B.V. on behalf of Xi’an Jiaotong University.